Antiviral properties of two trimeric recombinant gp41 proteins

Retrovirology
Delphine Delcroix-GenêteCécile Rousseau

Abstract

As it is the very first step of the HIV replication cycle, HIV entry represents an attractive target for the development of new antiviral drugs. In this context, fusion inhibitors are the third class of anti-HIV drugs to be used for treatment, in combination with nucleoside analogues and antiproteases. But the precise mechanism of HIV fusion mechanism is still unclear. Gp41 ectodomain-derived synthetic peptides represent ideal tools for clarifying this mechanism, in order to design more potent anti-HIV drugs. Two soluble trimeric recombinant gp41 proteins, termed Rgp41B and Rgp41A were designed. Both comprise the N- and C-terminal heptad repeat regions of the ectodomain of HIV-1 gp41, connected by a 7-residue hydrophilic linker, in order to mimic the trimeric fusogenic state of the transmembrane glycoprotein. Both recombinant proteins were found to inhibit HIV-1 entry into target cells in a dose-dependent manner. Rgp41A, the most potent inhibitor, was able to inhibit both X4 and R5 isolates into HeLa cells and primary T lymphocytes. X4 viruses were found to be more susceptible than R5 isolates to inhibition by Rgp41A. In order to elucidate how the trimeric recombinant gp41 protein can interfere with HIV-1 entry into target cell...Continue Reading

References

Aug 1, 1991·The Journal of Experimental Medicine·Q J Sattentau, J P Moore
Mar 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·T K HartP J Bugelski
Nov 23, 1990·Science·J P MooreQ J Sattentau
Jun 1, 1990·AIDS Research and Human Retroviruses·E L DelwartT Gilmore
Oct 11, 1994·Proceedings of the National Academy of Sciences of the United States of America·C T WildT J Matthews
Dec 1, 1995·Nature Structural Biology·M LuP S Kim
Feb 17, 1997·The Journal of Experimental Medicine·R I ConnorN R Landau
May 22, 1997·Nature·W WeissenhornD C Wiley
Nov 14, 1997·Proceedings of the National Academy of Sciences of the United States of America·K TanM Lu
Apr 18, 1998·Nature Structural Biology·R A FurutaC D Weiss
Jun 18, 1998·Cell·D C Chan, P S Kim
Sep 29, 1999·Proceedings of the National Academy of Sciences of the United States of America·T W Chun, A S Fauci
Nov 30, 1999·Nature·T W ChunA S Fauci
Jan 7, 2000·Journal of Molecular Biology·Y Kliger, Y Shai
Oct 12, 2000·The Journal of Biological Chemistry·Y KligerY Shai
Mar 7, 2001·Science·M J RootP S Kim
Jun 8, 2001·Annual Review of Biochemistry·D M Eckert, P S Kim
Jun 20, 2001·Nature Reviews. Molecular Cell Biology·J P Moore, M Stevenson
Sep 27, 2001·Proceedings of the National Academy of Sciences of the United States of America·D M Eckert, P S Kim
Jul 19, 2002·The Journal of General Virology·Paul R Clapham, Aine McKnight
Mar 13, 2003·Molecular Biology of the Cell·Ruben M MarkosyanGrigory B Melikyan
Jul 2, 2003·Nature Medicine·Anthony S Fauci
Jul 16, 2003·The American Journal of Bioethics : AJOB·David Steinberg
Jul 23, 2003·Biochimica Et Biophysica Acta·Stephen A GalloRobert Blumenthal
Mar 20, 2004·Nature Reviews. Drug Discovery·Tom MatthewsDani Bolognesi
Dec 8, 2004·Current Pharmaceutical Design·Ralf Altmeyer
Jun 29, 2006·The Journal of Biological Chemistry·H Kirby Steger, Michael J Root

❮ Previous
Next ❯

Methods Mentioned

BETA
gel filtration
circular dichroism
ELISA
flow cytometry
Assay

Software Mentioned

System [UNK]

Related Concepts

Related Feeds

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.